Advancing the Detection and Monitoring of Traumatic Brain Injuries with Simoa® Technology

Publication Brief

 

The need for a more sensitive method of measuring NfL, a critical biomarker associated with traumatic brain injury (TBI), is becoming increasingly important as we continue to see a rise TBI's worldwide. Simoa® NfL blood test is seen by many as an ultra-sensitive, accurate, and non-invasive method to detect NfL proteins. Researchers can now push the boundary of detection well beyond the current limit, thus allowing the examination of critical proteins at ultra-low, even baseline, levels. Download our flyer to learn more and to view a sampling of peer-reviewed studies employing Simoa® technology for TBI research.

By submitting the form you agree to Quanterix’s Terms and Conditions. If you have subscribed to our email marketing you can unsubscribe at any time, and you can learn more about how we manage your personal details in our Privacy Policy.